Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Precigen Inc's Business Segments
Precigen Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2025
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2025
- Reportable100%
Revenue by Reportable Segment - Q2 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 1 | 100% |
Revenue by Product & Service Category - Q2 FY2025
- Service95.2%
- Exemplar4.8%
- Product4.8%
Revenue by Product & Service Category - Q2 FY2025
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Service | $ 1 | 95.2% |
| Exemplar | $ 0 | 4.8% |
| Product | $ 0 | 4.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Precigen Inc
Precigen Inc., formerly known as Intrexon Corporation, is a biotechnology company based in Germantown, Maryland. It was founded in 1998 by Dr. Thomas Reed with a vision to develop cutting-edge technologies to address some of the world's most pressing challenges in health, energy, and the environment.
Precigen is renowned for its expertise in synthetic biology, a discipline that involves engineering and designing biological systems, organisms, or molecules to perform specific functions. The company leverages this technology to create innovative solutions in various fields, including healthcare, agriculture, industrial biotechnology, and environmental conservation.
In the healthcare sector, Precigen is dedicated to developing advanced therapies for serious diseases. They focus on gene therapies, CAR-T cell therapies, and biologics, aiming to provide safer and more effective treatment options for patients. Their therapeutic pipeline includes candidates for conditions such as cancer, cardiovascular diseases, genetic disorders, and infectious diseases.
The company's agriculture division, named AgBio, is committed to transforming the agricultural industry by enhancing crop productivity, reducing the environmental impact of farming practices, and improving food security. Precigen applies its synthetic biology expertise to engineer crops with traits such as increased yield, drought resistance, disease resistance, and nutritional enhancements. Their efforts aim to create sustainable agricultural solutions with a focus on precision and efficiency.
Industrial biotechnology is another key area of focus for Precigen. They develop bio-based products and processes that offer alternative, more sustainable options to traditional petrochemical-based methods. These include biofuels, renewable chemicals, and bioplastics. By harnessing the power of synthetic biology, Precigen aims to help reduce greenhouse gas emissions, decrease dependence on non-renewable resources, and promote a circular economy.
Additionally, Precigen is actively involved in environmental conservation efforts. They collaborate with various organizations and researchers to apply their synthetic biology expertise to protect and restore ecosystems. For example, they work on projects aimed at preserving endangered species, restoring damaged habitats, and mitigating the impacts of climate change on vulnerable ecosystems.
As a company, Precigen prides itself on its commitment to responsible and ethical innovation. They prioritize safety, quality, and compliance in all their endeavors, adhering to rigorous scientific standards and regulatory requirements. Their multidisciplinary team of scientists, engineers, and experts collaborate closely to push the boundaries of synthetic biology and develop solutions that address complex challenges.
Overall, Precigen Inc. is a leading biotechnology company that leverages the power of synthetic biology to develop innovative solutions in healthcare, agriculture, industrial biotechnology, and environmental conservation. Their work spans a wide range of applications, and they are driven by a mission to transform industries and create a positive impact on society.
Precigen is renowned for its expertise in synthetic biology, a discipline that involves engineering and designing biological systems, organisms, or molecules to perform specific functions. The company leverages this technology to create innovative solutions in various fields, including healthcare, agriculture, industrial biotechnology, and environmental conservation.
In the healthcare sector, Precigen is dedicated to developing advanced therapies for serious diseases. They focus on gene therapies, CAR-T cell therapies, and biologics, aiming to provide safer and more effective treatment options for patients. Their therapeutic pipeline includes candidates for conditions such as cancer, cardiovascular diseases, genetic disorders, and infectious diseases.
The company's agriculture division, named AgBio, is committed to transforming the agricultural industry by enhancing crop productivity, reducing the environmental impact of farming practices, and improving food security. Precigen applies its synthetic biology expertise to engineer crops with traits such as increased yield, drought resistance, disease resistance, and nutritional enhancements. Their efforts aim to create sustainable agricultural solutions with a focus on precision and efficiency.
Industrial biotechnology is another key area of focus for Precigen. They develop bio-based products and processes that offer alternative, more sustainable options to traditional petrochemical-based methods. These include biofuels, renewable chemicals, and bioplastics. By harnessing the power of synthetic biology, Precigen aims to help reduce greenhouse gas emissions, decrease dependence on non-renewable resources, and promote a circular economy.
Additionally, Precigen is actively involved in environmental conservation efforts. They collaborate with various organizations and researchers to apply their synthetic biology expertise to protect and restore ecosystems. For example, they work on projects aimed at preserving endangered species, restoring damaged habitats, and mitigating the impacts of climate change on vulnerable ecosystems.
As a company, Precigen prides itself on its commitment to responsible and ethical innovation. They prioritize safety, quality, and compliance in all their endeavors, adhering to rigorous scientific standards and regulatory requirements. Their multidisciplinary team of scientists, engineers, and experts collaborate closely to push the boundaries of synthetic biology and develop solutions that address complex challenges.
Overall, Precigen Inc. is a leading biotechnology company that leverages the power of synthetic biology to develop innovative solutions in healthcare, agriculture, industrial biotechnology, and environmental conservation. Their work spans a wide range of applications, and they are driven by a mission to transform industries and create a positive impact on society.
Precigen Inc. is a biotechnology company known for its innovative gene therapy and engineered immunotherapy solutions. Established to harness the power of genetic science, Precigen aims to address significant medical needs through advanced therapeutic products and services. Below is an extensive overview of the company’s main segments, products, and services:
Segments
1. Therapeutics:
- This segment includes the development of therapeutic products focused on treating various diseases, particularly in oncology, autoimmune diseases, and infectious diseases. The company invests in research and clinical trials to create transformative therapies that target the underlying genetic causes of diseases.
2. Gene Therapy:
- Precigen is engaged in developing gene therapies that can potentially correct or replace faulty genes responsible for disease. This segment emphasizes the use of its proprietary platforms to deliver therapeutic genes efficiently and effectively into patient cells.
3. Immuno-oncology:
- Within this segment, Precigen focuses on treatments that harness the immune system to fight cancer. The immuno-oncology pipeline includes therapies designed to enhance or modify the immune response to tumor cells, which can potentially lead to improved patient outcomes in cancer treatment.
4. Synthetic Biology:
- This segment encompasses the design and engineering of biological systems for practical applications in medicine and beyond. Precigen employs synthetic biology to create new therapeutic candidates by utilizing engineered cells that can perform specific functions within the body.
Products
1. PRGN-3005:
- This is an investigational gene therapy product focused on treating cancers by targeting the human papillomavirus (HPV). It aims to provoke a robust immune response against HPV-positive tumors.
2. PRGN-3006:
- Similar to PRGN-3005, this therapy is tailored for HPV-positive malignancies, aiming to effectively engage the immune system in recognizing and attacking tumor cells.
3. PRGN-2012:
- This product focuses on treating solid tumors and is designed to stimulate a robust anti-tumor immune response. It utilizes a unique platform that enables the delivery of genetic material directly into the patient’s immune cells.
4. Ultrasafe™ Technology:
- Precigen’s proprietary platform technology designed to facilitate the safe delivery of genes. This platform is integral to the effectiveness of their gene therapy offerings, ensuring that the therapeutic interventions are both efficient and safe for patients.
Services
1. Clinical Trials:
- Precigen conducts extensive clinical trials to advance its therapeutic candidates through various phases of research. They collaborate with clinical partners, research institutions, and healthcare providers to evaluate the efficacy and safety of their innovations.
2. Research Collaboration:
- The company actively seeks partnerships with academic institutions, industry leaders, and research facilities to expand its pipeline and leverage external expertise in developing new therapies.
3. Regulatory Support:
- Precigen has teams dedicated to navigating the complex regulatory environment surrounding biotechnology. They provide guidance through the regulatory processes involved in bringing new therapies to market, including interactions with agencies like the FDA.
4. Manufacturing and Process Development:
- The company invests in advanced manufacturing capabilities to produce their gene therapy products. This includes developing robust processes to ensure consistent and scalable production of therapeutic products.
5. Personalized Medicine Approaches:
- Precigen is increasingly focusing on personalized medicine through its technologies, aiming to tailor treatments to individual patients based on genetic and molecular profiling. This approach enhances treatment efficacy and minimizes adverse effects.
By focusing on these segments, products, and services, Precigen Inc. strives to be at the forefront of biotechnological innovation, addressing unmet medical needs and improving patient outcomes through advanced therapeutic solutions.
Segments
1. Therapeutics:
- This segment includes the development of therapeutic products focused on treating various diseases, particularly in oncology, autoimmune diseases, and infectious diseases. The company invests in research and clinical trials to create transformative therapies that target the underlying genetic causes of diseases.
2. Gene Therapy:
- Precigen is engaged in developing gene therapies that can potentially correct or replace faulty genes responsible for disease. This segment emphasizes the use of its proprietary platforms to deliver therapeutic genes efficiently and effectively into patient cells.
3. Immuno-oncology:
- Within this segment, Precigen focuses on treatments that harness the immune system to fight cancer. The immuno-oncology pipeline includes therapies designed to enhance or modify the immune response to tumor cells, which can potentially lead to improved patient outcomes in cancer treatment.
4. Synthetic Biology:
- This segment encompasses the design and engineering of biological systems for practical applications in medicine and beyond. Precigen employs synthetic biology to create new therapeutic candidates by utilizing engineered cells that can perform specific functions within the body.
Products
1. PRGN-3005:
- This is an investigational gene therapy product focused on treating cancers by targeting the human papillomavirus (HPV). It aims to provoke a robust immune response against HPV-positive tumors.
2. PRGN-3006:
- Similar to PRGN-3005, this therapy is tailored for HPV-positive malignancies, aiming to effectively engage the immune system in recognizing and attacking tumor cells.
3. PRGN-2012:
- This product focuses on treating solid tumors and is designed to stimulate a robust anti-tumor immune response. It utilizes a unique platform that enables the delivery of genetic material directly into the patient’s immune cells.
4. Ultrasafe™ Technology:
- Precigen’s proprietary platform technology designed to facilitate the safe delivery of genes. This platform is integral to the effectiveness of their gene therapy offerings, ensuring that the therapeutic interventions are both efficient and safe for patients.
Services
1. Clinical Trials:
- Precigen conducts extensive clinical trials to advance its therapeutic candidates through various phases of research. They collaborate with clinical partners, research institutions, and healthcare providers to evaluate the efficacy and safety of their innovations.
2. Research Collaboration:
- The company actively seeks partnerships with academic institutions, industry leaders, and research facilities to expand its pipeline and leverage external expertise in developing new therapies.
3. Regulatory Support:
- Precigen has teams dedicated to navigating the complex regulatory environment surrounding biotechnology. They provide guidance through the regulatory processes involved in bringing new therapies to market, including interactions with agencies like the FDA.
4. Manufacturing and Process Development:
- The company invests in advanced manufacturing capabilities to produce their gene therapy products. This includes developing robust processes to ensure consistent and scalable production of therapeutic products.
5. Personalized Medicine Approaches:
- Precigen is increasingly focusing on personalized medicine through its technologies, aiming to tailor treatments to individual patients based on genetic and molecular profiling. This approach enhances treatment efficacy and minimizes adverse effects.
By focusing on these segments, products, and services, Precigen Inc. strives to be at the forefront of biotechnological innovation, addressing unmet medical needs and improving patient outcomes through advanced therapeutic solutions.